📰 Dave Fredrickson News
Page 2 - Dave Fredrickson News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dave Fredrickson. Real-time updates on events, politics, business and more.
April 8, 2024
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can’t be removed with surgery, the company said. These patients have already received prior treatment and don’t have any good alternatives.
April 8, 2024
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.
April 8, 2024
Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. Its the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities.
April 6, 2024
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...
April 6, 2024
Based on three Phase II trials of AstraZeneca and Daiichi Sankyos Enhertu which showed clinically meaningful responses across a broad range of tumours ...
April 6, 2024
This is the fifth indication for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo and AstraZeneca) approved by the FDA.
March 31, 2024
Cambridge: AstraZenecas Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or...
February 21, 2024
The FDA greenlit the Tagrisso/chemo regimen in treatment-naive EGFR-mutant NSCLC, bolstering AstraZeneca’s flagship brand against would-be rivals.
February 19, 2024
By Ian Walker AstraZeneca shares are up and leading the FTSE 100 index risers after the company said that its lung-cancer treatment Tagrisso, together with...